Kelly Stahl
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kelly Stahl has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Chan Shen
Department of Surgery, College of Medicine, The Pennsylvania State University, Hershey, PA 17033, USA
7 shared publications - Elizabeth Josephine Olecki
Department of Surgery, Roswell Park Comprehensive Cancer Institute, Buffalo, NY
3 shared publications Elizabeth Olecki
Department of Surgery, College of Medicine, The Pennsylvania State University, Hershey, PA, USA
3 shared publicationsDaleela Dodge
Department of Surgery, College of Medicine, The Pennsylvania State University, Hershey, PA, USA
2 shared publicationsElizabeth J. Olecki
College of Medicine, Department of Surgery, The Pennsylvania State University, Hershey, Pennsylvania
2 shared publications- June S. Peng
Division of Surgical Oncology, Department of Surgery, Penn State College of Medicine, Hershey, Pennsylvania, USA
2 shared publications
Latest Publications
- 1 February 2022
- Published by Elsevier in Journal of Surgical Research
- Vol. 270, 22-30
Insurance Status and Travel Distance to Single Treatment Facility Predictive of Mastectomy
- 1 February 2022
- Published by Elsevier in Journal of Surgical Research
- Vol. 270, 22-30
Insurance Status and Travel Distance to Single Treatment Facility Predictive of Mastectomy
- 1 October 2021
- Published by Elsevier in Journal of Surgical Research
- Vol. 266, 168-179
Survival Benefit of Guideline-Concordant Postoperative Radiation for Local Merkel Cell Carcinoma
- 1 October 2021
- Published by Elsevier in Journal of Surgical Research
- Vol. 266, 168-179
Survival Benefit of Guideline-Concordant Postoperative Radiation for Local Merkel Cell Carcinoma
- Open Access
- 24 December 2020
- Published by MDPI AG in Current Oncology
- Vol. 28 (1) , 138-151
Gastric Cancer Treatments and Survival Trends in the United States
Gastric cancer is the third most common cause of cancer deaths worldwide. Despite evidence-based recommendation for treatment, the current treatment patterns for all stages of gastric cancer remain largely unexplored. This study investigates trends in the treatments and survival of gastric cancer. The National Cancer Database was used to identify gastric adenocarcinoma patients from 2004–2016. Chi-square tests were used to examine subgroup differences between disease stages: Stage I, II/III and IV. Multivariate analyses identified factors associated with the receipt of guideline concordant care. The Kaplan–Meier method was used to assess three-year overall survival. The final cohort included 108,150 patients: 23,584 Stage I, 40,216 Stage II/III, and 44,350 Stage IV. Stage specific guideline concordant care was received in only 73% of patients with Stage I disease and 51% of patients with Stage II/III disease. Patients who received guideline consistent care had significantly improved survival compared to those who did not. Overall, we found only moderate improvement in guideline adherence and three-year overall survival during the 13-year study time period. This study showed underutilization of stage specific guideline concordant care for stage I and II/III disease.
- 24 December 2020
- Published by MDPI AG in Current Oncology
- Vol. 28 (1) , 138-151
Open AccessGastric Cancer Treatments and Survival Trends in the United States
Gastric cancer is the third most common cause of cancer deaths worldwide. Despite evidence-based recommendation for treatment, the current treatment patterns for all stages of gastric cancer remain largely unexplored. This study investigates trends in the treatments and survival of gastric cancer. The National Cancer Database was used to identify gastric adenocarcinoma patients from 2004–2016. Chi-square tests were used to examine subgroup differences between disease stages: Stage I, II/III and IV. Multivariate analyses identified factors associated with the receipt of guideline concordant care. The Kaplan–Meier method was used to assess three-year overall survival. The final cohort included 108,150 patients: 23,584 Stage I, 40,216 Stage II/III, and 44,350 Stage IV. Stage specific guideline concordant care was received in only 73% of patients with Stage I disease and 51% of patients with Stage II/III disease. Patients who received guideline consistent care had significantly improved survival compared to those who did not. Overall, we found only moderate improvement in guideline adherence and three-year overall survival during the 13-year study time period. This study showed underutilization of stage specific guideline concordant care for stage I and II/III disease.
- 30 October 2020
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 28 (5) , 2646-2658
Benefits of Surgical Treatment of Stage IV Breast Cancer for Patients With Known Hormone Receptor and HER2 Status
For the 6% of breast cancer patients with a diagnosis of stage IV disease, systemic therapy is the cornerstone of treatment, with an unclear role for surge
- 30 October 2020
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 28 (5) , 2646-2658
Benefits of Surgical Treatment of Stage IV Breast Cancer for Patients With Known Hormone Receptor and HER2 Status
For the 6% of breast cancer patients with a diagnosis of stage IV disease, systemic therapy is the cornerstone of treatment, with an unclear role for surge
- 28 October 2020
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 28 (5) , 2659
ASO Author Reflections: Surgery Offers Survival Advantage in Treatment-Responsive Metastatic Breast Cancer
- 28 October 2020
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 28 (5) , 2659
ASO Author Reflections: Surgery Offers Survival Advantage in Treatment-Responsive Metastatic Breast Cancer
- Open Access
- 1 October 2020
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 231 (4) , S173-S174
Upstaging in Early-Stage Pancreatic Cancer: Risk Factors and Effect on Survival
Up to 70% of clinically stage I (cStage) pancreatic cancer patients are upstaged to a higher pathologic stage (pStage). Despite a majority of patients being upstaged after resection, risk factors and the effect of upstaging on overall survival (OS) are not well defined.
- 1 October 2020
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 231 (4) , S173-S174
Open AccessUpstaging in Early-Stage Pancreatic Cancer: Risk Factors and Effect on Survival
Up to 70% of clinically stage I (cStage) pancreatic cancer patients are upstaged to a higher pathologic stage (pStage). Despite a majority of patients being upstaged after resection, risk factors and the effect of upstaging on overall survival (OS) are not well defined.
- Open Access
- 1 October 2020
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 231 (4) , S284-S285
Upstaging Effect on the Receipt of Guideline-Concordant Care and Survival in Early Stage Gastric Cancer
- 1 October 2020
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 231 (4) , S284-S285
Open AccessUpstaging Effect on the Receipt of Guideline-Concordant Care and Survival in Early Stage Gastric Cancer
- 26 August 2020
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 28 (3) , 1581-1592
Undertreatment of Pancreatic Cancer: Role of Surgical Pathology
Current guidelines recommend treatment of early-stage pancreatic cancer with surgical resection and chemotherapy. Undertreatment can occur after resection
- 26 August 2020
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 28 (3) , 1581-1592
Undertreatment of Pancreatic Cancer: Role of Surgical Pathology
Current guidelines recommend treatment of early-stage pancreatic cancer with surgical resection and chemotherapy. Undertreatment can occur after resection
- 5 May 2020
- Published by Springer Nature
- p. 145-163
Surgical Recovery